Mylan NDEA contamination prompts Teva recall in US

By Flora Southey

- Last updated on GMT

(Image: Getty/ChrisSteer)
(Image: Getty/ChrisSteer)

Related tags Recall Teva pharmaceutical industries Mylan

Teva is the latest firm to recall valsartan products after a probable carcinogen was detected in its supplier’s API.

Teva Pharmaceuticals USA has issued a voluntary nationwide recall​ of all amlodipine/valsartan combination tablets and amlodipine/vastartan/hydrochlorothiazide combination tablets within expiry. Both combination products are used for the treatment of high blood pressure.

According to Teva, the presence of N-nitroso-diethylamine (NDEA) – classified by the International Agency for Research on Cancer as a probable carcinogen​ – in the products’ valsartan active pharmaceutical ingredient (API), prompted the recall.

The contaminated API was manufactured by Mylan in Hyderabad, India. This same contamination was also detected by EU authorities, which last week, made the decision to suspend​ the use of Mylan’s Hyderabad-made valsartan in Europe.

Mylan is the latest API manufacturer to be affected by NDEA, or related compound N-nitrosodimethylamine (NDMA), contaminations, after impurities were found in Chinese firm Zhejiang Huahai Pharmaceuticals’​ valsartan, and Indian firms Hetero Labs​ and Aurobindo Pharma Limited​’s losartan and irbesartan, respectively.

Manufacturing concerns

In a separate GMP issue, earlier this month the US Food and Drug Administration (FDA) sent Mylan a warning letter relating to the firm’s manufacturing facility in Morgantown, West Virginia.

The letter references a Form 483 with thirteen observations​ issued by US regulators in April this year. According to the Mylan, the company has implemented “comprehensive restructuring and remediation” ​at its Morgantown facility.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more